CTLA4 and melanoma: Since 2011, the FDA and EMA have approved four new immunotherapies for patients with the advanced melanoma, including the anti-CTLA-4 antibody ipilimumab (Yervoy), the anti-PD-1 antibodies nivolumab (Opdivo) and pembrolizumab (Keytruda), and the oncolytic virus talimogene laherparepvec (TVEC, Imlygic)1.